Trial Profile

Feasibility of Cetuximab (ERBITUX) Associated With Concomitant Radio-chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer: a Phase II, Randomised Study.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Etoposide; Vinorelbine
Indications Non-small cell lung cancer
Focus Adverse reactions

Most Recent Events

18 Oct 2012 Status changed from recruiting to completed.
02 Oct 2012 Final results presented at the 37th Congress of the European Society for Medical Oncology.
21 Jun 2012 Additional company (Merck KGaA) added in association as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com